NCT02109250View on ClinicalTrials.gov

CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice

CompletedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Metastatic Medullary Thyroid Cancer
Interventions
DRUG

Caprelsa

Caprelsa® 100 mg or 300 mg film-coated oral tablets. Each film-coated tablet contains 100 mg or 300 mg of vandetanib.

Trial Locations (8)

1000

Institut Jules Bordet, Brussels

1090

UZ Brussel, Brussels

1200

UCL St-Luc, Brussels

2930

AZ Klina, Brasschaat

6700

Clinique du Sud Luxembourg, Arlon

7500

CH de Wallonie, Tournai

8800

AZ Delta, Roeselare

9000

UZ Gent, Ghent

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT02109250 - CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice | Biotech Hunter | Biotech Hunter